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Abstract
Chromosomal rearrangements deregulating hematopoietic transcription factors are common in 
acute lymphoblastic leukemia (ALL).1,2 Here, we show that deregulation of the homeobox 
transcription factor gene DUX4 and the ETS transcription factor gene ERG are hallmarks of a 
subtype of B-progenitor ALL that comprises up to 7% of B-ALL. DUX4 rearrangement and 
overexpression was present in all cases, and was accompanied by transcriptional deregulation of 
ERG, expression of a novel ERG isoform, ERGalt, and frequent ERG deletion. ERGalt utilizes a 
non-canonical first exon whose transcription was initiated by DUX4 binding. ERGalt retains the 
DNA-binding and transactivating domains of ERG, but inhibits wild-type ERG transcriptional 
activity and is transforming. These results illustrate a unique paradigm of transcription factor 
deregulation in leukemia, in which DUX4 deregulation results in loss-of-function of ERG, either 
by deletion or induction of expression of an isoform that is a dominant negative inhibitor of wild 
type ERG function.
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INTRODUCTION
B-precursor ALL is the commonest childhood tumor, and is a heterogeneous disease 
comprising multiple subtypes with distinct constellations of somatic structural DNA 
rearrangements and sequence mutations that commonly perturb lymphoid development, 
cytokine receptor and Ras signaling, tumor suppression and chromatin modification.2 
However, the genetic basis of a substantial proportion of B-ALL cases remains to be 
defined. Previous reports identified a subset of B-ALL with a distinct gene expression 
profile,3 and frequent deletion of ERG, encoding the ETS-family transcription factor v-ets 
avian erythroblastosis virus E26 oncogene.4–6 ERG has a key role in hematopoietic 
differentiation5,7,8, megakaryopoiesis,9 and megakaryoblastic leukemia associated with 
Down syndrome10–12. ERG is frequently rearranged in carcinoma of the prostate13 and 
rarely in acute leukemia14, and ERG overexpression is associated with poor outcome in 
acute myeloid leukemia15. ERG is temporally regulated during B lymphopoiesis 
(Supplementary Figure 1), suggesting it may regulate B lymphoid development, however its 
role in the pathogenesis of ALL is unknown.
RESULTS
A subtype of B-ALL with DUX4 rearrangement and ERG deletion
To understand the genetic basis of this subtype of B-ALL, we studied a cohort of 1913 
individuals with B-progenitor ALL, including 1347 children, 395 adolescents (age 16–20) 
and 171 young adults (age 21–39) with B-progenitor ALL using gene expression profiling 
and analysis of DNA copy number alterations by single nucleotide polymorphism (SNP) 
arrays in all cases, and whole genome (N=32), exome (N=44) and/or transcriptome 
sequencing (N=54) in a subset of cases (Supplementary Tables 1–2).
Microarray and transcriptome sequencing data identified 141 (7.6%) ALL cases with a 
distinct gene expression profile (Figure 1a–b, Supplementary Table 3 and Supplementary 
Figure 2). This form of leukemia constituted 5.2% of childhood standard risk, 9.4% of 
childhood high risk, 10.2% of adolescent and 5.4% of adult ALL cases.
Eighty-five (55.6%) of these cases had focal deletions of ERG at chromosome 21q22.3 
(Figure 1c–d), which were not observed in other B- or T-ALL cases. The ERG deletions 
were confirmed by genomic quantitative PCR and breakpoint mapping, and most commonly 
involved exons 3–7 (N=27) or 3–9 (N=22) of ERG transcript variant 1 (NM_182918.3, the 
most abundantly expressed transcript in non-B ALL and normal B cells)5,16. The presence of 
conserved heptamer recombinase signal sequences at deletion breakpoints and intervening 
non-consensus nucleotides indicated that the deletions arise from aberrant recombinase 
activating gene activity (data not shown). Genomic analysis of a panel of leukemia cell lines 
showed the B-progenitor cell line NALM-6 exhibited a similar gene expression profile and 
an intragenic ERG deletion (Supplementary Figure 3).
Notably, genes of the double homeobox gene family on chromosomes 4q/10q were among 
the top upregulated genes (Figure 2a and Supplementary Table 3). Analysis of transcriptome 
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sequencing data showed that all cases sequenced exhibited rearrangement of DUX4 to IGH, 
placing DUX4 under the control of the immunoglobulin heavy chain enhancer resulting in 
increased expression of DUX4 (Supplementary Table 2). DUX4 encodes a double 
homeobox transcription factor located in a macrosatellite repeat in the subtelomeric repeat 
unit of chromosome 4q.17 Deletion of part of this repeat unit is causative of 
facioscapulohumeral dystrophy, and DUX4 rearrangements have been reported in a subset of 
Ewing-like sarcoma (CIC-DUX4),18,19 and recently, a subset of ALL.20 In each case of this 
subtype, DUX4 is inserted adjacent to the IGH enhancer region (see Supplementary Note 
and Supplementary Figure 4a), with variable truncation of the C-terminus of DUX4 and 
appending of a variable number of amino acids from read-through into the IGH locus (See 
Supplementary Note, Figure 2b–d). IGH-DUX4 rearrangement was confirmed in all 6 cases 
selected for validation by RT-PCR and/or genomic PCR (Supplementary Table 4 and 
Supplementary Figure 4b–c), and DUX4 overexpression was confirmed by immunoblotting 
(Figure 2d). Thus, DUX4 rearrangement is a universal feature of this subtype of B-ALL that 
exhibits a distinct gene expression profile, with deletion of ERG identified in the majority of 
cases.
The genomic landscape of DUX4-rearranged B-ALL
Analysis of genome, exome and transcriptome data demonstrated that in addition to 
universal rearrangement of DUX4 and frequent deletion of ERG, this subtype of ALL is 
characterized by a distinct mutational landscape (Figure 3). We identified a mean of 17.5 
non-silent sequence mutations per case (range 2–42) and a paucity of structural genetic 
alterations (Supplementary Tables 5–9). Alterations of lymphoid transcription factor genes 
were present in 46.5% of cases (IKZF1 36.7% and PAX5 11.3%). Notably, while IKZF1 
alterations are associated with poor outcome in other subtypes of childhood B-ALL21,22, 
they were not associated with poor outcome in childhood DUX4/ERG ALL (Supplementary 
Figure 5). Mutations in transcription factors and transcriptional regulators were observed in 
21% of DUX4/ERG cases, including MYC, MYCBP2, MGA and ZEB2, that were 
uncommon in other subtypes of B-ALL, including 209 representative B-ALL and 16 T-ALL 
cases subjected to whole genome or exome sequencing (a listing of recurrently mutated and 
deleted genes across ALL subtypes is provided in Supplementary Table 10). Additional 
recurrent mutations included those activating Ras signaling (35.2%), cell cycle regulation 
(22.5%); and epigenetic modifiers (56.3%), most commonly KMT2D, SETD2, ARID2 and 
NCOR1 (Supplementary Figure 6).
ERG deregulation in DUX4-rearranged B-ALL
DUX4-rearranged cases also exhibited profound transcriptional deregulation of ERG. 
Although the absolute level of expression of ERG was not higher in comparison to other 
ALL subtypes, this subtype of ALL was characterized by expression of multiple aberrant 
coding and non-coding ERG isoforms. Using RT-PCR, we detected internally deleted ERG 
transcripts corresponding to the exon 3–7 and 3–9 deletions (Supplementary Figure 7a). 
Translation of these internally truncated transcripts was predicted to result in a frame shift 
and premature truncation. However, corresponding N-terminal truncated ERG proteins were 
not identified on immunoblotting of leukemic cells harboring ERG deletions (data not 
shown). In contrast, immunoblotting using C-terminus specific antibodies identified a 28 
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kDa ERG protein in 50 (63.2%) of 79 DUX4/ERG ALL cases tested, including cases 
lacking an ERG deletion, suggesting an alternate mechanism of ERG deregulation 
(Supplementary Figure 7b).
Of the 54 DUX4-rearranged cases subjected to transcriptome sequencing, the majority 
expressed aberrant ERG transcripts initiated in intron 6 (Supplementary Table 11). The most 
abundantly expressed isoform was initiated from a novel exon whose 3’ splice site was 
located 197 nucleotides proximal to exon 7 (exon 6 alternate, or exon 6 alt; Figure 4a). The 
genomic boundaries of this non-canonical exon were determined by rapid amplification of 
cDNA ends (RACE), RT-PCR with primer walking, and analysis of the orientation of RNA-
seq read pairs mapping to this region. This confirmed splicing of exon 6 alt to exon 7 and 
downstream exons, without evidence for splicing of upstream exons into exon 6 alt, 
indicating that exon 6 alt is a non-canonical first exon (Supplementary Figure 8).
RT-PCR demonstrated in-frame splicing from ERG exon 6 alt to exon 7, resulting in 
expression of an ERG protein with a new N-terminus of 7 amino acids encoded by exon 6 alt 
followed by exons 7 through 10 of ERG isoform 1 (“ERGalt a”; Figure 4b). The predicted 
size of this truncated C-terminal ERG protein corresponded to the size of the protein 
identified by immunoblotting of ERG ALL leukemic cells (Supplementary Figure 7c).
We next systematically analyzed expression of canonical and non-canonical ERG transcripts 
across a range of leukemias and solid tumors using data from the St Jude Children’s 
Research Hospital – Washington University Pediatric Cancer Genome Project. In addition to 
ERGalt a, we identified a second isoform with coding potential also encoded using ERG 
exon 6 alt, ERGalt b, and two less abundant transcripts that lack coding potential (ERG alt 
c/d, Figure 4c, Supplementary Table 11). Expression of the coding isoforms, ERG alt a/b, 
was observed in the majority of ERG ALL cases, and accounted for the majority of 
transcripts expressed in such cases, but was uncommon and low level in non-ERG cases, 
such as a minority of BCR-ABL1 ALL cases (Figure 4d). Analysis of other pediatric ALL 
(N=290) and non-hematopoietic (N=572) tumors showed that expression of non-canonical 
ERG transcripts were observed in a minority of other B-ALL cases (e.g. Ph+ ALL) but were 
usually comprised of transcripts without coding potential. In contrast high-level expression 
of ERG transcripts initiated from this exon was restricted to DUX4-rearranged cases, which 
was confirmed by quantitative RNA-sequencing and quantitative RT-PCR (Supplementary 
Table 12).
Additional evidence of ERG deregulation was observed, with intron retention upstream of 
ERG exon 7 (Supplementary Figure 9). Analysis of total stranded RNA-sequencing data of 
12 DUX4/ERG, 40 other B-ALL cases and normal B cell progenitors identified expression 
of a long non-coding RNA proximal to the first exon of ERG in the majority of DUX4/ERG 
cases that was restricted to this form of leukemia, and observed in cases with and without 
ERG deletion (Antisense Long non-coding RNA associated with ERG, or ALE; 
Supplementary Tables 12–13 and Supplementary Figures 10–11).
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DUX4 binds and induces deregulation of ERG
The finding of DUX4 rearrangement as a universal feature of this subtype of ALL, and the 
unique presence of ERG deregulation and deletion suggests that the two phenomena are 
related and may contribute to leukemogenesis. DUX4 is known to induce deregulated 
expression of many genes, including transcripts utilizing alternate exons.23
To examine the relationship of DUX4 expression and ERG deregulation, we first analysed 
previously reported chromatin immunoprecipitation and sequencing (ChIP-seq) data for 
DUX4 expressed in human myoblasts.23 This identified a peak of DUX4 binding at the first, 
non-canonical exon of ERGalt with two DUX4 binding motifs within this 372 nucleotide 
region (Supplementary Figure 12). Moreover, analysis of RNA-seq data showed that 
expression of DUX4 in myoblasts resulted in expression of ERGalt that was not observed in 
non-DUX4 expressing cells (Supplementary Figure 13a). Using ChIP-PCR, we observed 
binding of DUX4 to the first exon of ERGalt in NALM-6 cells (Supplementary Figure 13b). 
We next performed DUX4 ChIP-seq in NALM-6 and Reh (ETV6-RUNX1 ALL) cells that 
confirmed DUX4 binding at ERG exon 6 alt (Figure 5a), as well as at additional transcripts 
deregulated in DUX4/ERG ALL (Supplementary Figure 13c). A comprehensive listing of all 
peaks of DUX4 binding identified by ChIP-seq annotated with DUX4/ERG gene expression 
and ATAC-seq data is provided in Supplementary Table 14.
We systematically analyzed the expression of transcripts utilizing non-canonical first exons 
in total stranded RNA-seq data, and identified 45 transcripts significantly deregulated in 
DUX4/ERG ALL, of which three (ERG, NSD1 and RNGTT) were bound by DUX4 
(Supplementary Table 15). ERGalt was the second most frequently deregulated transcript 
utilizing a non-canonical first exon, and the most frequently deregulated of those loci bound 
by DUX4.
To examine the role of DUX4 overexpression in deregulation of ERG, we transduced human 
cord blood hematopoietic cells and the ETV6-RUNX1 B-ALL cell line Reh with lentiviral 
vectors expressing DUX4 alleles corresponding to those identified in patients (DUX4 E415* 
and Q334*), and empty lentiviral vector as a control. Truncated DUX4 induced expression 
of ERGalt in both Reh and human CD34 cord blood cells, as shown by both transcript and 
protein analysis (expression of full length DUX4 was not tolerated in 293T vector producer 
cells) (Figure 5b–c Supplementary Figure 13d).
Together, these findings suggest that ERG deregulation is caused by DUX4 overexpression, 
which binds to the alternative transcription initiation site in ERG intron 6, and that ERG 
deletion is a secondary event occurring in a transcriptionally active locus primed for RAG-
mediated deletion. Such deletion of ERG may further impair expression of wild-type ERG. 
Consistent with this proposed mechanism and sequence of deregulation, transcription of 
ERGalt is initiated in ERG intron 6, which lies in the common regions of ERG deletion 
(exons 3–7 and 3–9). Thus, in contrast to other key targets of deletion in ALL such as PAX5 
and IKZF1, the deleted ERG allele cannot encode the putative oncogenic isoform, but rather 
it is encoded by the non-deleted ERG allele.
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In addition, some DUX4/ERG cases expressing ERGalt lack a clonal ERG deletion but have 
evidence of subclonal deletions. Of the 46 of 54 cases with transcriptome data that express 
ERGalt, 27 had a clonal ERG deletion. However, 7 cases lacking such a deletion had 
evidence of a subclonal deletion on genomic PCR (Supplementary Table 2), and emergence 
of clonal ERG deletions was observed in xenografted cases, and in cases of relapsed ALL in 
which the characteristic gene expression profile was present at both diagnosis and relapse, 
but in which clonal ERG deletions were only observed at relapse (data not shown). Together, 
these data support the notion that ERG deletions are secondary genomic events, but if 
acquired sufficiently early in leukemogenesis may be present as clonal events.
ERGalt inhibits activity of ERG and promotes leukemogenesis
ERGalt lacks the N-terminal pointed domain and central regulatory domains of wild type 
ERG, but retains the DNA-binding ETS and transactivation domains. Both wild-type ERG 
and ERGalt exhibited nuclear localization and bound DNA target sequences (Supplementary 
Figure 14a and data not shown). In a transcriptional reporter assay using an ERG target 
gene, gpIX24, ERGalt displayed diminished transactivating activity and acted as a 
competitive inhibitor of wild type ERG (Supplementary Figure 14b–c).
These results suggest that ERGalt may directly contribute to leukemogenesis, in part by 
inhibiting the function of wild-type ERG. To explore this, lineage-negative bone marrow 
from Arf−/− mice was transduced with retroviral supernatants expressing wild type ERG or 
ERGalt, and/or an activated NRAS allele and/or IK6, the dominant negative form of IKZF1 
commonly observed in human ALL, followed by in vitro culture and transplantation of 
transduced cells into lethally irradiated recipients. ERGalt and NRASG12D together 
promoted serial replating of lymphoid cells (Supplementary Figure 15). Consistent with 
prior reports, expression of wild type ERG induced a lethal erythromegakaryoblastic 
leukemia (Figure 6a–d)25. In contrast, mice transplanted with ERGalt expressing cells 
developed lymphoid precursor, biphenotypic or pre-B cell leukemias with longer latency 
(Figure 6a–d), indicating ERGalt directly promotes lymphoid leukemogenesis.
Discussion
These data provide comprehensive genomic characterization of a subtype of B-progenitor 
ALL characterized by a distinct gene expression profile and deregulation of two 
transcription factors, DUX4 and ERG. Our findings indicate that DUX4 rearrangement is 
present in all cases with this distinct gene expression profile, and is a clonal event acquired 
early in leukemogenesis. DUX4 is not expressed during normal mouse or human B cell 
development, and translocation to IGH provides a mechanism for hijacking into the B cell 
lineage, as we have previously described for other genes rearranged to antigen receptor loci 
such as CRLF2 and EPOR.26–29
The striking deregulation and deletion of ERG is unique to this subtype of ALL. While 
multiple prior studies have reported ERG deletions in B-ALL,22,30–32 including in DUX4-
rearranged cases,33 several of these studies have identified only cases harboring the common 
deletions and used these as a surrogate to identify a subset of ALL cases with favorable 
prognosis.30,31 In contrast, we show that ERG transcriptional deregulation is a hallmark of 
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this subtype, with diverse ERG deletions in a majority, but not all cases. Multiple 
mechanisms of ERG genomic alteration were observed. These included expression of 
aberrant ERG transcripts in all cases, including non-canonical coding transcripts, 
deregulation with intron retention, and long non-coding RNA expression, with expression of 
the novel coding ERG transcript, ERGalt, in the majority of cases; and clonal or subclonal 
ERG deletions also observed in the majority of cases. We have shown that DUX4 directly 
binds to the ERG locus at the first, non-canonical exon of ERGalt, and in multiple 
hematopoietic and non-hematopoietic cell types directly induces expression of ERGalt. The 
deregulation of ERG by DUX4 is reminiscent of deregulation of other ETS family genes in 
solid tumors,19 and represents a new mechanism of ETS gene deregulation in leukemia. 
Moreover, as ERG may represent one of potentially many genes deregulated by DUX4, we 
performed a systematic, genome-wide, integrated analysis of gene expression, expression of 
genes utilizing non-canonical first exons, DUX4 ChIP-seq and ATAC sequencing and show 
that ERGalt is the top deregulated gene in this form of leukemia that is bound by DUX4 and 
utilizes a non-canonical first exon.
The observations that ERG is deleted in only a subset of cases, and that expression of 
ERGalt is directly induced by DUX4 suggests that ERG deregulation is an important, but 
secondary event in leukemogenesis. In addition, we have shown that for the majority of 
cases harboring an ERG deletion, deregulation of the ERG locus involves both alleles, and 
cannot be explained by perturbation of a single copy of the gene. The common ERG 
deletions remove intron 6 which harbors ERG exon 6 alt, the first exon encoding ERGalt, 
and the region bound by DUX4. Thus, in a case with a clonal ERG deletion, ERGalt must be 
expressed from the non-deleted ERG allele. Thus, our data suggest a sequence of events in 
which rearrangement of DUX4 is an early, leukemia-initiating event that results in binding 
to the ERG locus and deregulated expression of coding and non-coding transcripts. The 
resulting increased chromatin accessibility evidenced by ATAC-sequencing renders the locus 
susceptible to RAG-mediated deletion of ERG. Should this occur early in leukemogenesis, 
ERG deletion is observed as a clonal event, but if later, a subclonal event that may become 
clonal during disease progression (e.g. at relapse, or as a surrogate, passage in an 
immunocompromised mouse).
The interplay of DUX4 and ERG deregulation in leukemogenesis will require detailed future 
examination in appropriately engineered mouse models that must account for the fact that 
ERG exon 6 alt is incompletely conserved in the mouse, and primary mouse hematopoietic 
cells were thus not suited to examining induction of ERG alt by DUX4. That 
notwithstanding, the findings of inhibition of the transcriptional activity of wild-type ERG 
by ERGalt, and documentation of aberrant intron retention and/or deletion of ERG in all 
cases in this form of leukemia, but rarely in any other tumor indicate that inhibition or loss 
of ERG activity is required in the pathogenesis of human DUX4/ERG ALL. The notion that 
ERGalt sustains lymphoid colony replating, and induces leukemia with longer latency than 
wild type ERG, but with a shift to a biphenotypic or lymphoid lineage, further supports this 
notion.
These findings have important clinical implications, as DUX4/ERG ALL is associated with 
favorable outcome, irrespective of the presence of concomitant genetic alterations otherwise 
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associated with poor outcome in other contexts, such as deletion of IKZF1. DUX4 
rearrangement is not evident on karyotypic analysis, and is challenging to identify on 
analysis of genome and RNA-sequencing data due to the repetitive nature of both 
breakpoints and the nature of DUX4 insertion into the IGH locus. Thus, in contrast to prior 
studies that have used identification of only the common (and clonal) ERG deletions as a 
surrogate for identification of a distinct type of leukemia,30,31 future studies must move 
beyond identification of ERG deletions alone to identify this form of leukemia. All cases 
harbor rearrangement of DUX4, detection of which requires transcriptome and/or genome 
sequencing. Quantitation of DUX4 may also identify cases with rearrangements, but must be 
performed carefully in view of the highly paralogous nature of the DUX family of genes. 
Conventional cytogenetic approaches such as fluorescence in situ hybridization are 
challenging due to the repetitive nature of DUX4 locus. Identification of such cases, 
however, is important and to accurately assign risk and guide therapy.
ONLINE METHODS
Patients and samples
Diagnosis and remission samples were obtained from St Jude Children’s Research Hospital, 
the Children’s Oncology Group, the Alliance – Cancer and Leukemia Group B, the Eastern 
Cooperative Oncology Group and the MD Anderson Cancer Center. We examined leukemia 
samples obtained at diagnosis from 1913 children (age up to age 16), adolescents (age 16–
21) and young adults (age 21–39) with B-progenitor ALL (Supplementary Table 1) using 
microarray gene expression profiling and single nucleotide polymorphism array analysis. 
The study was approved by the St Jude Institutional Review Board and informed consent 
was obtained from patients or legal guardians.
Genomic analysis
Whole genome, whole exome, and transcriptome sequencing, and gene expression and SNP 
array analysis were performed as previously described.29,30 Additional details of 
bioinformatic analysis are provided in the Supplementary Note. The genomic landscape was 
summarized using ProteinPaint34.
Whole genome and/or exome sequencing was performed for ERG-altered B-ALL cases 
(N=72 cases), ETV6-RUNX1 ALL (54), ALL with high hyperdiploidy (39), BCR-ABL1 
ALL (39), ALL with low hypodiploidy or near haploid karyotypes (N=19), TCF3-PBX1 
ALL (N=17), BCR-ABL1-like ALL (17), miscellaneous B-ALL (N=17), T-lineage ALL 
(N=17) and B-ALL with rearrangement of CRLF2 (7). Paired end whole genome 
sequencing of tumor and normal DNA was performed using HiSeq 2000 genome sequencers 
(Illumina) as previously described to at least 30 fold haploid coverage. Exome sequencing 
was performed using Truseq exome capture baits (Illumina) and GAIIx or HiSeq 2000 
sequencers as previously described35. Sequence mapping and variant calling was performed 
as described35,36. Data were visualized in ProteinPaint.37
Transcriptome sequencing was performed for 175 B-ALL cases including ERG-altered cases 
(54 cases), ETV6-RUNX1 (N=54), BCR-ABL1-positive and BCR-ABL1-like ALL (N=27 
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each), hypodiploid ALL (N=8), high hyperdiploid and miscellaneous ALL (N=5). Total 
RNA was extracted from leukemia cells using TRIzol (Life Technologies, NY). Total RNA 
quality and quantity were assessed on Agilent RNA6000 Chip (Agilent, CA) and Qubit 
(Life). RNA-Seq was prepared from 1 µg total RNA following Illumina RNA-Seq protocols 
including DNase treatment and Phenol purification, PolyA+ RNA selection by using Oligo-
dT beads, cDNA conversion, fragmentation by Covaris Ultrasonicator (Covaris, MA), end 
repairing, deoxyadenosine tailing, adaptor ligation and PCR amplification (10 cycles). The 
library with 10 pM was clustered on Illumina cBot and the flowcell was loaded on HiSeq for 
sequencing using Illumina 2×100bp sequencing kit (Illumina, CA).
Transcriptome sequencing data were mapped to the human genome (hg19) using in-house 
software, and the resulting alignments were analyzed to identify evidence of both known and 
novel splicing events. Predicted splice junction sites were post-processed with a software 
package called RNApeg to correct mapping ambiguities and apply minimum quality control 
requirements to novel junction calls. RNApeg evaluates junctions for microhomologous 
mapping ambiguity versus reference junctions in the refGene, ENSEMBL, AceView, and 
UCSC known gene databases, also correcting against novel exon skips and single-edge 
matches in those isoforms. Novel junctions without any available reference anchoring are 
compared with each other and across samples, facilitating standardized comparison. Where 
ambiguity was identified, coordinates are adjusted and supporting read evidence is 
combined, producing a more compact and consistent set of junction calls.
The transcript expression levels in transcriptome sequencing data were estimated as 
Fragments Per Kilobase of transcript per Million mapped reads (FPKM). Briefly, the read 
counts in the GENCODE annotated gene model were obtained with the HTseq-count 
program.38 The FPKM values were computed by normalizing the obtained read counts of 
the transcripts or genes with the length of the transcripts or genes and the total mapped 
reads.
A gene was called “expressed” in a given sample if it had a FPKM value ≥0.35 based on the 
distribution of FPKM gene expression levels and filtered out genes that were not expressed 
in any sample from the final gene expression data matrix for downstream analysis. Similar to 
expression arrays, limma39 with estimation of false-discovery rate (FDR)40 was also 
performed between ERG and other B-ALL samples (FDR<0.05).
Total stranded RNA sequencing was performed for 6 B lymphoid progenitor samples flow 
sorted from human bone marrow, 12 ERG ALL and 40 non ERG B-ALL cases. Expression 
levels of ERGalt and ALE were examined in 922 hematopoietic, brain and solid tumor cases 
sequenced by the St Jude Washington University Pediatric Cancer Genome Project, and 
adult tumor cases sequenced by The Cancer Genome Atlas (non-small cell adenocarcinoma, 
N=308, squamous non-small cell lung cancer, N=279, low grade glioma, N=467, 
glioblastoma multiforme, GBM N=167 and ovarian cancer, N=15).
ATAC sequencing
ATAC (assay for transposase-accessible chromatin) sequencing was performed using cell 
lines (NALM-6, Reh) and xenografts of DUX4/ERG ALL as previously described with 
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minor modifications 41. NALM-6 and Reh were obtained from the Leibniz Institute DSMZ – 
German Collection of Microorganisms and Cell Cultures and were subjected to SNP array 
and transcriptome sequencing, and tested for Mycoplasma spp. contamination prior to use. 
Briefly, 50,000 cells were lysed and isolated nuclei were resuspended in 2× TD buffer. 
Transposase reactions were purified using MinElute columns (Qiagen) and library fragments 
amplified using NEB Next HiFi 2× MM (New England Biosciences), with quantitative PCR 
cycle optimization performed using Kapa SybrFast 2× MM (Kapa Biosystems). Post 
amplification products were purified using two rounds of incubation with the Agencourt 
Ampure XP SPRI beads at a 1.4× ratio (Beckman Coulter). The libraries were quantified via 
Qubit HS DNA kit (Life Technologies), and evaluated for library size distribution on a 
Bioanalyzer 2100 (Agilent Technologies). Sequencing was performed on a HiSeq 2000 
(Illumina) generating paired 100 nucleotide reads.
Reads were aligned to hg19 with BWA with default parameters after trimming illumina 
adapter sequences. Observed fragment size showed similar enrichment of nucleosome free, 
mononucleosome, dinucleosome, trinucleosome as described.41 Reads were adjusted by 
transposon inserts offset, and the unique aligned nucleosome free fragments of less than 100 
nucleotides in size were extraacted. Wig files were generated by extending these nucleosome 
free fragments to 80bp from the center and uploaded to UCSC Genome Browser for 
visualization. For annotation of DUX4 binding sites, we called nucleosome free regions 
considering every nucleosome free fragments as two single-end reads and called nucleosome 
free regions with MACS242 (version 2.1.0.20150603; default parameters with “--extsize 200 
--nomodel”).
Establishment of DUX4/ERG xenografts
Eight xenografts of human DUX4/ERG ALL were established using NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (NOD-SCID gamma-null, or NSG) mice.43 Primary leukemia cells were 
intravenously injected in NSG mice and engraftment monitored by flow cytometric analysis 
of peripheral blood using antibodies against human CD19 and CD45. Engraftment was 
monitored by retro orbital bleeding after 4 weeks, and then every 2–4 weeks as necessary 
and xenograft cells were harvested when levels of peripheral blood engraftment exceeded 
50%.
Cloning and expression of DUX4 in human cord blood samples
All cord blood samples were obtained with informed consent according to procedures 
approved by the institutional review boards of the University Health Network, Trillium 
Health Centre, Brampton Civic Hospital, and Credit Valley Hospital, Ontario, Canada. 
Mononuclear cells were obtained by centrifugation on Lymphoprep medium (Stem Cell 
Technologies) and were depleted of Lin+ cells (lineage depletion) by negative selection with 
the StemSep Human Progenitor Cell Enrichment Kit according to the manufacturer’s 
protocol (Stem Cell Technologies). Lin− CB cells were stored at −150°C. Lin− cells were 
thawed by drop-wise addition of X-VIVO 10 (Lonza), 50% HyClone Cosmic Calf Serum, 
100 µg/ml DNase (Roche) and were cultured at a cell density of 1.6 – 2.5×106/mL in X-
VIVO 10 medium supplemented with 1% BSA (Roche), L-glutamine (GIBCO), Pen/Strep 
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(GIBCO), and the following cytokines (all from Miltenyi): SCF (100 ng/ml), Flt3L (100 ng/
ml), TPO (50 ng/ml) and IL7 (IL-7; 10 ng/ml).
For lentiviral overexpression studies a pRRL based and Gateway® (ThermoFisher) adapted 
lentiviral vector was used in which transgene expression is driven by the SFFV promoter and 
tagBFP by a chimeric EF1α/SV40 promoter (J.E.D., K.K., ST., E.W., manuscript in 
preparation). The cDNA of wild type and truncated DUX4 were PCR amplified from 
leukemic cell RNA and were inserted via Gateway® LR clonase reaction according to 
manufacturer’s instructions (ThermoFisher). VSV-G pseudotyped lentiviral vector particles 
were produced by polyethyleneimine (PEI) based co-transfection of 10.5 µg pMD.G2, 20.5 
µg pCMVR8.74 (both Addgene) and 38 µg transfer vector into HEK-293T cells44 and 
titrated on MOLM-13 cells. For transduction, pre-stimulated (15 hrs) CB Lin- cells 
(4×105/mL) were exposed to virus for 32 hrs at an MOI of 4.5 resulting in 22–78% BFP+ 
cells at day 4 post transduction when cells were sorted on FACSAria II (Becton Dickinson) 
to obtain BFP+ and BFP− fractions for RNA (5×104) and protein lysates (0.9-5.6×106).
Chromatin immunoprecipitation assays
ChIP assays were carried out as described previously.45 Chromatin shearing was performed 
according to the truChIP shearing protocol (Covaris; http://covarisinc.com/wp-content/
uploads/pn_010179.pdf) with minor modification. Briefly, 25×106 Reh and NALM6 cells 
were incubated for 10 min in 1% formaldehyde in phosphate buffered saline at room 
temperature, quenched by adding 1/10 volume of 2.5 M glycine. The cells were then washed 
three times by cold phosphate buffered saline containing proteinase inhibitors and lysed on 
ice for 10 minutes in lysis buffer (50 mM HEPES PH7.9, 140 mM NaCl, 1 mM EDTA, 10% 
glycerol, 0.5% NP-40, 0.25% Triton-X100). Chromatin was washed twice in washing buffer 
(10 mM TrisCl, pH 8, 200 mM NaCl,1 mM EDTA, 0.5 mM EGTA), then twice in shearing 
buffer (0.1% SDS, 10 mM TrisCl, pH8, 1 mM EDTA) before resuspension in 1 mL shearing 
buffer. Chromatin was sonicated in 1 ml AFA millitubes using a Covaris E210 instrument for 
20 mintues at 5% duty cycle, intensity 4, 200 cycles per burst at 7°C. The sheared chromatin 
was spun down 10 minutes at 13,000 rpm, 4°C and the supernatant was mixed with equal 
amount of ChIP-dilution buffer (0.1% SDS, 30 mM TrisCl, pH 8, 1 mM EDTA, 300 mM 
NaCl) before ChIP experiments. Immunoprecipitation was performed with a DUX4 
antibody (ab124699) and a normal rabbit IgG control (Santa Cruz).
Real-time PCR (ΔCt method) was employed to determine the enrichment of human ERG 
locus by antibodies for DUX4. The signals were normalized to input as percentile. The 
primers used are shown in Supplementary Table 16.
To prepare ChIP-seq libraries, 10 ng of ChIP DNA was end-repaired and adapter ligation 
performed using the NEBNext® ChIP-Seq Library Prep Reagent Set for Illumina® (New 
England Biosciences). Libraries were purified after 14 rounds of PCR amplification with Q5 
DNA Hot Start polymerase (New England Biosciences). Each ChIP-seq library underwent 
50-cycle single-end sequencing using TruSeq SBS kit V3 on the Illumina Hiseq 2000.
Sequence reads were aligned to human genome hg19 (GRCh37) by BWA46 (version 0.5.9-
r26-dev using default parameter), and duplicated reads were then marked with Picard 
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(version 1.65(1160)) and only non-duplicated reads retained for analysis (using SAMtools47 
(parameter “-q 1 -F 1024” version 0.1.18 (r982:295)). Cross-correlation plots were generated 
by a non-duplicated version of SPP48 (version 1.11) for quality control (QC) and fragment 
sizes estimated using caTools (version 1.17) and bitops (version 1.0–6) implemented in R 
(version 2.14.0). The best fragment size estimated by the cross-correlation plot were used to 
extend each read to generate bigwig files for viewing in Integrative Genomics Viewer49 
(version 2.3.40), with scaling of the height of bigwig tracks by normalization to 15 million 
non-duplicated reads. All results of quality control analysis and visualization indicated our 
data passed ENCODE criteria except for Reh DUX4-ChIP seq, where results were similar to 
input DNA used as a conrol (relative strand correlation < 1) which was as expected due to 
the lack of DUX4 expression in this cell line. For annotation, MACS2 was used for peak 
calling (again using input DNA as a control) and only peaks overlapping in the two 
replicates for NALM6 were retained and merged as finalized peaks. MAST50 in the MEME 
suite51 (version 4.10.2) was used for scanning DUX4 motifs (JASPAR52 accession 
MA0468.1) within finalized NALM6 DUX4 ChIP-seq peaks.
Fluorescent in situ hybridization
Fluorescence in situ hybridization for disruption of the ERG locus was performed for 10 
novel BALL cases in the training cohort using diagnostic bone marrow or peripheral blood 
leukemic cells in Carnoy’s fixative as previously described32. BAC clones RP11-50G3 (5’ of 
ERG) and RP11-720N21 (3’ of ERG) were labelled with rhodamine and fluorescein 
isothiocyanate, respectively. At least 100 interphase nuclei were scored per case.
RT-PCR and cloning
Wild type ERG, ERGalt and ALE were amplified using Advantage 2 DNA polymerase 
(Clontech, Mountain View, CA) as previously described32. PCR primers are listed in 
(Supplementary Table 16). PCR products were purified, and sequenced directly and after 
cloning into pGEM-T-Easy (Promega) and subcloned into MSCV-IRES-GFP retroviral 
vectors.
Luciferase assays
Twenty four hours after plating 20,000 293T cells per well in a 96-well plate, cells were 
transfected with equimolar amounts of ERG wild type (MIG-ERG isotype 1), mutant (MIG-
ERG-e6alt) or MIG empty vector along with 250 ng of pGL3-gpIX luciferase reporter 
plasmid and 50 ng of pRL-TK Renilla luciferase plasmid DNA (Promega) using Fugene 6 
Transfection Reagent (Roche Diagnostics, Alameda, CA). Competition assays were 
performed by transfecting increasing amounts of mutant ERG plasmid together with a fixed 
amount of wild type ERG plasmid or vice versa complemented with empty vector. Forty-
eight hours post-transfection, cell lysis and measurement of firefly and Renilla luciferase 
activity was performed using the Dual-Glo® Luciferase Assay System (Promega) according 
to the manufacturer’s instructions. Transfections were performed in triplicate in at least two 
independent experiments. The firefly luciferase - Renilla luciferase ratio was reported as 
mean ± s.e.m.
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Immunofluorescence and immunoblotting
Cytospins of pre-B cells were fixed with 4% paraformaldehyde and washed with phosphate-
buffered saline (PBS), followed by a 30 minute incubation in a blocking/permeabilization 
solution of 10% normal goat serum (NGS)/0.1% Triton-X 100/PBS, and then incubated for 
one hour with primary ERG antibody (Abcam EPR3864) diluted in 3% NGS/0.1% Triton-X 
100/PBS. Slides were washed three times in PBS, and then incubated for 45 minutes in 3% 
NGS/0.1% Triton-X 100/PBS containing a secondary antibody conjugated to Ig-Alexa Fluor 
555 (Invitrogen). Slides were washed three times in PBS and mounted with Vectashield 
(Vector Labs) containing 4’-6-diamidino-2-phenylindol (DAPI). All steps were carried out at 
room temperature. Images were captured using a Nikon C2 confocal fluorescence 
microscope.
Immunoblotting of cell line and leukemic cell whole cell lysates was performed as 
previously described32,53 using ERG N-terminus specific antibodies (C20 and H95, Santa 
Cruz Biotechnologies, Santa Cruz, CA), and a C-terminus specific rabbit monoclonal 
antibody (Abcam 133264). DUX4 immunoblotting was performed with a C-terminus 
specific (E5-5, ab124699, Abcam) and N-terminus specific (aa82–131, LS-C205474, 
Lifespan Biosciences, Inc.) antibodies.
Gene Transduction and Transplantation of Lineage-negative Bone Marrow Cells
Mice were housed in an American Association of Laboratory Animal Care (AALAC)-
accredited facility and were treated on Institutional Animal Care and Use Committee 
(IACUC)-approved protocols in accordance with NIH guidelines. For in vivo lineage-
negative cell transplantation experiments, bone marrow from 8-week-old Arf−/− mice54 was 
extracted from tibiae and femora. Red blood cells were lysed and the remaining bone 
marrow cells were incubated with a cocktail of biotinylated anti-mouse antibodies (Gr-1, 
B220, Ly-1, Ter119, Mac-1; BD Biosciences, San Jose, CA) followed by mixing with 
streptavidin-coated beads (Dynabeads M-280 Streptavidin, Dynal 112.16; Life 
Technologies, Grand Island, NY). Cells were separated on a magnet, and unbound cells were 
collected and incubated at 37°C, 5% CO2 for two days in the presence of IL-3, IL-6, SCF, 
IL-7, and Flt3 cytokines (Peprotech; Rocky Hill, NJ). Cells were retrovirally-transduced 
with MIG-ERG WT or MIG-ERGalt on RetroNectin (Takara Bio, Otsu Shiga, Japan) for 48 
hours priors to sorting for GFP-positive cells (BD FACSAria, BD Biosciences, San Jose, 
CA). Recipient 10-week-old wildtype C57Bl/6 mice were lethally irradiated (11 Gy) 24 
hours prior to transplantation with 200,000 GFP-positive cells via tail-vein injection. 
Animals were not randomized prior to transplantation. Animals were monitored, without 
blinding, for the development of leukemia clinically by measurement of GFP expression in 
peripheral blood and sacrificed when moribund, or at the end of the study. Post-mortem flow 
analysis for B220, CD19, Mac-1, Gr-1, Ter119, and Thy1 was performed on the GFP-
positive population of bone marrow and spleen samples to determine lineage of disease. 
GraphPad Prism v.6 software was utilized to generate Kaplan-Meier survival curves and 
Mantel-Cox p values for pairwise comparisons of cohorts.
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Lineage-negative enrichment and colony assays of murine haematopoietic cells
Bone marrow mononuclear cells were harvested from 10-week old Arf−/− mice and labeled 
with biotin-conjugated lineage antibodies (Ly-6G and Ly-6C, CD11b, CD45R/B220, CD5, 
TER-119; BD Biosciences, San Jose, CA), followed by incubation with streptavidin coated 
magnetic beads (Dynabeads M-280 Streptavidin; Thermo Fisher Scientific Inc., Franklin, 
MA). Lineage-negative cells were purified by magnetic separation and cultured for 48 hours 
in Iscove’s Modified Dulbecco’s Medium/20% fetal bovine serum supplemented with 
penicillin-streptomycin, L-glutamine, recombinant mouse stem cell factor (SCF; 50 ng/ml), 
FLT-3 ligand (40 ng/ml), IL-6 (30 ng/ml), IL-3 (20 ng/ml), and IL-7 (10 ng/ml) (Peprotech, 
Rocky Hill, NJ). Cells were infected on RetroNectin-coated plates for 48 hours (Takara Bio 
Inc., Shiga, Japan) with MSCV-IRES-GFP (MIG) and MSCV-IRES-RFP (MIR) retroviruses 
expressing the following: wild-type, NRASG12D, ERGwt, ERGe6alt, tricistronic vector of 
ERGwt and NRASG12D, and ERGe6alt and NRASG12D for MIG; wild-type and IK6 (isoform 
derived from IKZF1 deletion of exon4-7) for MIR. These combinations resulted in twelve 
conditions. Transduced GFP and RFP-positive cells were obtained by fluorescence-activated 
cell sorting. For clonogenic assays, 10,000 cells were plated in triplicate in Methocult 
M3231 (Stem Cell Technologies, Inc., Vancouver, BC, Canada) with the appropriate factors 
(SCF, 100 ng/ml; IL-7, 20 ng/ml; FLT-3 ligand, 10 ng/ml) and colonies were scored 7 days 
later. For re-plating, 10,000 cells were cultured in identical conditions, with colonies 
counted on day 10–12. Colony identity was confirmed by morphological analysis through 
cytospin and Wright-Giemsa staining and by flow analysis for a panel of multi-lineage 
markers (Gr-1-PerCPCy5.5, Ter119-PE-Cy7, B220-eFluor605, CD3-APC, Mac1-Alexa700 
and CD19-APC-Cy7) and specific B-cell lineage markers (CD43-PerCP-Cy5.5, IgM-PE-
Cy7, and BP1-Alexa647).
Statistical analysis
Associations between categorical variables were examined using Fisher’s exact test. 
Associations between DUX4/ERG status with treatment outcome (event free survival and 
relapse) were performed as previously described55–59. Differences in survival between mice 
transplanted with ERG wild type or ERG alt transduced cells were compared using the 
Mantel Cox test. Analyses were performed using Prism v6.0 (Graphpad, La Jolla, CA), R 
(www.r-project.org)60, SAS (SAS v9.1.2, SAS Institute, Cary, NC) and SPLUS (SPLUS 7.0, 
Insightful Corp., Palo Alto, CA) and StatXact (v 8.0.0, Cytel Inc, Cambridge, MA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Gene expression profile and ERG deletions in DUX4/ERG ALL
a, Hierarchical clustering of the top 100 Affymetrix U133A probe sets upregulated in each 
subtype of 199 B- and T-lineage ALL cases, including DUX4/ERG ALL. b, Principal 
component analysis of FPKM gene expression data derived from poly-A RNA sequencing 
identifying DUX4/ERG ALL c, SNP microarray data of cases with ERG deletions. Data for 
each case is shown as a column, and shown in a log2 ratio scale where deletions are blue. 
The position of the ERG locus is shown as an arrow on the left of the panel, and genomic 
coordinates shown in megabases on the right. Cases are ordered from left to right according 
to the extent of the deletion, with focal exon 1 deletions on the left, the common exons 3–7 
and 3–9 deletions in the middle of the panel, and whole gene deletion on the right. d, 
Representative DNA copy number data of four cases with ERG deletion also shown in log2 
ratio scale, with probe level data shown, deletion being below the x axis. The extent of 
deletion in each case is shown by horizontal bars.
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Figure 2. Rearrangement of DUX4
a, deregulation of DUX4 is observed exclusively in the ALL cases with ERG deregulation. 
Gene expression data shown as fragments per kilobase of mapped reads (FPKM) from RNA-
sequencing in box plots, with ALL cases grouped by subtype on the x axis. Horizontal lines 
show median, and the boxes, interquartile range. b, an example of the commonly complex 
rearrangements of IGH and DUX4. Each third of the panel shows RNA-seq gene expression 
data for three loci involved in the rearrangement. The top shows increased expression at 
DUX4. The dotted line shows the breakpoint of DUX4 that is juxtaposed to a small segment 
of CDH4 shown in the middle panel, which in turn is rearranged to IGH, shown in the lower 
panel. c, schematic showing the location of the breakpoints in DUX4, stratified by age 
group. d, Immunoblotting of cell line and primary leukemic sample lysates showing proteins 
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of variable size corresponding to DUX4 C-terminal truncation and/or appending with amino 
acid residues encoded by read through into the IGH locus.
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Figure 3. Structural and sequence alterations in DUX4/ERG ALL
Heatmap showing genomic data for DUX4/ERG ALL cases, each of which is represented in 
a column and genes are grouped by functional pathway. The colors for each type of genetic 
alterations are shown at the bottom of the figure. The genomic profiling performed, and 
presence/absence of ERGalt, ALE and DUX4 rearrangement are shown at the top of the 
figure, where yellow represents assay performed (or alteration present), white, not 
performed or absent, and gray, data not available.
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Figure 4. Expression of ERGalt in DUX4/ERG ALL
a, read depth from mRNA-sequencing of an ERG ALL case with expression of exon 6 alt 
(red) and a case lacking ERG alt expression (gray). b, RT-PCR with PCR primers specific to 
exon 6 alt and exon 10, showing amplification of a larger amplicon in ALL cases lacking 
ERG alt, with amplification of the intervening intronic sequence between ERGalt and exon 
7, and a smaller amplicon in ERGalt positive cases arising from splicing from exon 6 alt to 
exon 7, shown in a representative electropherogram. This transcript results in a novel N-
terminus of ERG encoded by exon 6 alt comprising 7 residues spliced in frame to exons 7–
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10. c, structure of the canonical and ERG ALL-associated ERG transcripts and isoforms. d, 
relative abundance of ERG transcripts in ERG ALL and other B-ALL subtypes. Each 
column represents a case. The top panel represents expression of wild type (WT) ERG, and 
the middle panel expression of ERGalt, and the less abundant ERGalt isoforms. The lower 
panel shows the cumulative abundance of all isoforms as a proportion within each case. 
Transcripts arising from splicing across ERG deletion are low abundance in most cases with 
ERG deletion (with the exception of one case with biallelic deletion. Non-coding ERGalt 
isoforms are more common in ERG ALL cases lacking ERG deletion.
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Figure 5. DUX4 induces deregulation of ERG
a, DUX4 ChIP-seq and ATAC-sequencing data of Reh, NALM6 and DUX4/ERG ALL 
xenograft showing DUX4 binding at ERG exon 6 alt (arrowed) in NALM6 but not in Reh. 
ATAC sequencing showing open chromatin at this peak of DUX4 binding at ERG exon 6 alt 
in the DUX4/ERG xenograft sample and NALM6 but not in Reh. ATAC-seq data is provided 
in Supplementary Figure 19. b–c, expression of two truncated DUX4 alleles, but not empty 
vector, results in expression of ERGalt by RT-PCR (b) and immunoblotting (c). b, the top 
panel shows RT-PCR for ERG using primers specific for exon 6 alt and exon 7. In 
untransduced or empty vector transduced Reh cells, a larger amplicon is observed that 
incorporates the intervening intronic transcript (lanes 3 and 4). In DUX4/ERG ALL cells 
(PARLRH, lane 2) and DUX4-transduced Reh cells (lanes 5 and 6), ERGalt is amplified, 
with in-frame splicing from exon 6 alt to exon 7 (lower part of panel). c, Immunoblotting 
showing expression of ERGalt in cells transduced with DUX4. The top part of the panel 
shows immunoblotting with an N-terminus DUX4-specific antibody; the middle part 
blotting with a C-terminus specific ERG antibody, and the lower part, actin control. DUX4 
alleles induce expression of ERGalt in HEK293T cells (lanes 6 and 7) and Reh cells (lanes 
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11 and 12). Lane 5 shows 293T cells transfected with ERGalt virus as a positive control for 
ERGalt (and negative for DUX4); lane 8 shows DUX4/ERG patient sample PARLRH 
positive for DUX4 and ERGalt.
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Figure 6. Expression of ERGalt induces ALL
a, Transplantation of lineage negative Arf−/− progenitors induces erythromegakaryoblastic 
leukemia, and ERGalt expressing marrow a lymphoid progenitor, biphenotypic or B-
lymphoid leukemia. *** P< 0.0001 (Mantel-Cox); n= 12 ERG WT, 19 ERGalt mice from 2 
independent experiments. b, immunoblotting with a C-terminus specific ERG antibody for 
ERG ALL samples and splenocytes of mouse leukemias, showing expression of ERG alt in 
human ERG ALL and mouse tumors induced by expression of ERG alt. c, proportion of 
leukemias displaying erythromegakaryoblastic, lymphoid, or mixed immunophenotype 
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(mixed = lymphoid and myeloid subpopulations). d, representative immunophenotyping of 
ERG-induced tumors showing expression of the erythroid marker Ter119 in an ERG WT 
induced tumor, and coexpression of B220 and CD19 in ERGalt induced leukemia. Cells 
were gated on GFP expression.
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